Sandoz To Pump Another €50m Into Kundl Antibiotics Site
New Three-Floor Building For Penicillin FDFs Set To Open Early In 2024
Executive Summary
To increase manufacturing capacity for finished dosage form penicillins, Sandoz is investing another €50m into its key antibiotics site in Kundl, Austria. But the company feels that fundamental reforms are needed from regulators to ensure the long-term sustainability of European-based antibiotic manufacturing and supply.
You may also be interested in...
Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
Sandoz Chief Looks To Build On Recent Deals
With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.
Who’s Hired? Firms Ring In 2023 With Fresh Faces
The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.